Detects human IL‑36 beta /IL‑1F8 in direct ELISAs and Western blots. In direct ELISAs, less than 5% cross-reactivity with recombinant human (rh) IL-1 beta and rhIL-36 alpha is observed and less than 1% cross-reactivity with rhIL-36 gamma, rhIL-1 alpha and rhIL-18 is observed.
Polyclonal Goat IgG
E. coli-derived recombinant human IL‑36 beta /IL‑1F8 Met1-Glu157 Accession # Q3MIH0
Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied as a 0.2 µm filtered solution in PBS.
<0.10 EU per 1 μg of the antibody by the LAL method.
Recombinant Human IL‑36 beta /IL‑1F8 (Catalog # 1099-IL)
Immersion fixed paraffin-embedded sections of human tonsil subjected to Antigen Retrieval Reagent-Basic (Catalog # CTS013)
Blockade of Receptor-ligand Interaction
In a functional ELISA, 1.5-6 µg/mL of this antibody will block 50% of the binding of 5 μg/mL of Recombinant Human IL-1 Rrp2/IL-1 R6 Fc Chimera (Catalog # 872-RP) to immobilized Recombinant Human IL‑36 beta /IL‑1F8 (Catalog # 1099-IL) coated at 1 µg/mL (100 µL/well). At 100 μg/mL, this antibody will block >90% of the binding.
Measured by its ability to neutralize IL‑36 beta /IL‑1F8-induced IL-8 secretion in human pre-adipocytes. van Asseldonk, E.J. et al. (2010) Obesity 18:2234.The Neutralization Dose (ND50) is typically 50-300 ng/mL in the presence of 20 ng/mL Recombinant Human IL‑36 beta /IL‑1F8 (aa 5-157).
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Cell IL-8 Secretion Induced by IL‑36 beta /IL‑1F8 and Neutralization by Human IL‑36 beta / IL‑1F8 Antibody.
Recombinant Human IL‑36 beta / IL‑1F8 (aa 5-157) (Catalog # 6834-IL) induces IL-8 secretion in human pre-adipocytes in a dose-dependent manner (orange line). IL-8 Secretion elicited by Recombinant Human IL‑36 beta / IL‑1F8 (aa 5-157) (20 ng/mL) is neutralized (green line) by increasing concentrations of Goat Anti-Human IL‑36 beta /IL‑1F8 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF1099). The ND50 is typically 50‑300 ng/mL.
Preparation and Storage
Reconstitute at 0.2 mg/mL in sterile PBS.
The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
Stability & Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70 °C as supplied.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: IL-36 beta/IL-1F8
Human interleukin 1 family member #8 [IL-1F8; also named Interleukin-36 beta, IL36B, FIL-1 eta (eta) and IL-1H2] is a member of the IL-1 family of proteins (1‑3). IL-1 family members include IL‑1 beta, IL-1 alpha, IL-1ra, IL-18 and IL-1F5 through F10 (4). All family members show a 12 beta -stranded beta -trefoil configuration, and are believed to have arisen from a common ancestral gene that has undergone multiple duplications (4). Two alternatively spliced transcript variants encode distinct (164 or 157 residues) protein isoforms that differ in their C-terminal 70 amino acid (aa) residues have been reported (3). IL-1F8 isoform 2 is synthesized as a 157 aa protein that contains no signal sequence and no prosegment (1, 2). Unlike IL-1F8 isoform 1 which lacks potential N‑linked glycosylation sites, isoform 2 contains one potential N-linked glycosylation site in its unique C-terminus. IL-1F8 is reported to be actively secreted (1). Human IL-1F8 isoform 2 shares 61% aa identity with mouse IL-1 ra, a 183 aa form of IL‑1F8. Within the IL-1 family, IL-1F8 shares 30%, 32%, 37%, 46%, 34%, 45% and 28% aa sequence identity with IL-1 ra, IL-1 beta, IL-1F5, F6, F7, F9 and F10, respectively. Cells reported to express IL-1F8 include resting and activated monocytes and B cells (1, 4). The receptor for IL-1F8 is reported to be a combination of IL-1 Rrp2 and IL-1 RAcP (5). Recombinant IL-1F8, along with IL-1F6 and IL-1F9, has been shown to activate the pathway involving NF-kappa B and MAPK in an IL-1 Rrp2 dependent manner.
Smith, D.E. et al. (2000) J. Biol. Chem. 275:1169.
Kumar, S. et al. (2000) J. Biol. Chem. 275:10308.
Nicklin, M.J.H. et al. (2002) Genomics 79:718.
Dunn, E. et al. (2001) Trends Immunol. 22:533.
Towne, J.E. et al. (2004) J. Biol. Chem. 279:13677.
R&D Systems personnel manually curate a database that contains references using R&D Systems products.
The data collected includes not only links to publications in PubMed,
but also provides information about sample types, species, and experimental conditions.
The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.